Search Results

Among Intra-Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for major depressive disorder.

Intra-Cellular submitted its application to the FDA for Caplyta’s approval in major depressive disorder, potentially opening up an additional $1 billion in sales. Still, the stock remains “cheap,” according to Jefferies analysts.

Intra-Cellular Therapies, Inc. today announced the promotion of Michael Halstead, J.D. to the position of President.

Intra-Cellular Therapies, Inc. today announced that it will participate in three upcoming investor conferences.

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced that it will participate in two upcoming investor conferences.

Intra-Cellular Therapies, Inc. highlights data presentations at the American Society of Clinical Psychopharmacology Annual Meeting being held in Miami, May 28 - 31, 2024.

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced its financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET in New York, NY.

Intra-Cellular Therapies, Inc. announced that it has commenced an underwritten public offering of $500 million of shares of its common stock.